Heart Failure, Stable Angina
Conditions
Keywords
vaspin, visfatin, lipoprotein A, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A
Brief summary
The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.
Detailed description
* The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission in patients on empagliflozin 10 mg once daily for 6 months before the beginning of the study. * We enrolled a total of 60 patients with HF, 60 asymptomatic CAD patients and 60 healthy controls (HC) without cardiovascular diseases. Group I: 60 Healthy Subjects. Group II: 60 Patients with Stable Angina (asymptomatic CAD). Group III: 60 Patients with Heart Failure. * Clinical parameters, glycemic and lipid profile, vaspin, visfatin, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A and lipoprotein A levels were assayed. * Patients will be followed up to assess all-cause 30- and -90 day of hospital readmission.
Interventions
OTHERGroup I Healthy
Healthy Subjects
DRUGCAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Group II: Stable Angina Patients
DRUGHF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Group III: Heart Failure Patients
Sponsors
Tanta University
Damanhour University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Either sex, aged 18 years or older. * new-onset AHF or acute decompensation of chronic HF, * CAD (including previous myocardial infarction, previous percutaneous or surgical coronary revascularization, or angiographic evidence that one or more major coronary arteries had narrowed by 50% or more). * On empagliflozin 10 mg once daily for 6 months before the beginning of the study.
Exclusion criteria
* severe liver/ * kidney dysfunction; * severe systemic disease (such as the diseases of respiratory system/ digestive system/ nervous system etc.); * malignant tumor; * acute/ chronic infectious diseases; * autoimmune disease or connective tissue disease; * major trauma or surgical operation over the past three months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All Cause 30 day hosptial admission | 1 month | Number of patients admited to hospital during 1 month. |
| All Cause 90 day hosptial admission | 3 months | Number of patients admited to hospital during 3 month. |
| vaspin (ng/ml) | 1 month | vaspin blood concentration |
| visfatin (ng/ml) | 1 month | visfatin blood concentration |
| Sortillin (pg/ml) | 1 month | Sortillin blood concentration |
| Homocystien(umol/L) | 1 Month | Homocystien blood concentration |
| Troponin.I (ng/ml) | 1 Month | Troponin.I blood concentration |
Countries
Egypt
Outcome results
None listed